KFAS
CRSP icon

Keating Financial Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Keating Financial Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218 Buy
4
+1
+33% +$53 ﹤0.01% 2422
2026
Q1 		$143 Sell
3
-3
-50% -$158 ﹤0.01% 2390
2025
Q4 		$315 Buy
+6
New +$359 ﹤0.01% 2014

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Keating Financial Advisory Services's CRSP Position: Q2 2026 in Review

Keating Financial Advisory Services increased its CRISPR Therapeutics (CRSP) stake by 33% in Q2 2026, buying an estimated $53 and bringing the position to 4 shares worth $218. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

Keating Financial Advisory Services first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $315 in Q4 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Keating Financial Advisory Services held 4 shares of CRISPR Therapeutics worth $218 as of Q2 2026.
  • Keating Financial Advisory Services bought 1 CRISPR Therapeutics share in Q2 2026, an estimated $53.
  • CRISPR Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2422 holding.
  • Keating Financial Advisory Services first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's CRISPR Therapeutics position peaked at $315 in Q4 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.